Oral GPIIb/IIIa antagonists: What went wrong?

被引:52
作者
Cox, D [1 ]
机构
[1] Royal Coll Surgeons Ireland, Sch Pharm, Dept Clin Pharmacol, Dublin 2, Ireland
关键词
D O I
10.2174/1381612043384673
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
GPIIb/IIIa receptor antagonists block fibrinogen binding to platelets Bud as a result inhibit platelet aggregation. They are very potent inhibitors due to the critical role fibrinogen binding plays in platlet aggregation. When given intravenously these drugs have been shown to be very, effective as adjuvant therapy in percutaneous coronary intervention and in acute coronary syndromes. However, despite being as potent as their intravenous counterparts, all of the oral inhibitors showed no benefit or even increased mortality in clinical trials. There are a number of reasons for their failure. The target was different, chronic treatment to prevent thrombotic events as opposed to short-term treatment to prevent acute events and as a result. different Closing regimens Were used. The acute use aims I'm a high level of inhibition (80-90%) while the chronic use produced lower levels of inhibition. Many of the oral inhibitors had low bioavailability that led to a large peak-through difference. Most GPIIb/IIIa antagonists have the ability to activate platelets through a GPIIb/IIIa-mediated process. This is known as partial agonisin. In the presence or high drug levels, such as during an infusion this is not a problem, however combined with the low trough levels with oral inhibitors this call lead to all increase tit platelet aggregation. Other problems include drug-induced conformational changes in GPIIb/IIIa (ligand-regulated binding sites) and possible pharmacogenomics effects in the response to the drugs, in particular the pl(A) polymorphism in GPIIb/IIIa. By addressing these issues it is possible for a new generation of oral GPIIb/IIIa antagonist to be developed.
引用
收藏
页码:1587 / 1596
页数:10
相关论文
共 78 条
  • [1] Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation
    Adderley, SR
    Fitzgerald, DJ
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (08) : 5760 - 5766
  • [2] Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty
    Akkerhuis, KM
    van den Brand, MJBM
    van der Zwaan, C
    Peels, HOJ
    Suryapranata, H
    van der Wieken, LR
    Stibbe, J
    Hoffmann, J
    Baardman, T
    Deckers, JW
    Simoons, ML
    [J]. HEART, 2001, 85 (04) : 444 - 450
  • [3] Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation - A phase II study
    Akkerhuis, KM
    Neuhaus, KL
    Wilcox, RG
    Vahanian, A
    Boland, JL
    Hoffmann, J
    Baardman, T
    Nehmiz, G
    Roth, U
    Klootwijk, APJ
    Deckers, JW
    Simoons, ML
    [J]. EUROPEAN HEART JOURNAL, 2000, 21 (24) : 2042 - 2055
  • [4] Anders R, 2001, CARDIOVASC DRUG REV, V19, P116
  • [5] CD40L stabilizes arterial thrombi by a β3 integrin-dependent mechanism
    André, P
    Prasad, KSS
    Denis, CV
    He, M
    Papalia, JM
    Hynes, RO
    Phillips, DR
    Wagner, DD
    [J]. NATURE MEDICINE, 2002, 8 (03) : 247 - 252
  • [6] Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial
    Ault, KA
    Cannon, CP
    Mitchell, J
    McCahan, J
    Tracy, RP
    Novotny, WF
    Reimann, JD
    Braunwald, E
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (03) : 634 - 639
  • [7] Synthetic oligosaccharides as heparin-mimetics displaying anticoagulant properties
    Avci, FY
    Karst, NA
    Linhardt, RJ
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (28) : 2323 - 2335
  • [8] Baba K, 2001, CARDIOVASC DRUG REV, V19, P25
  • [9] Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
  • [10] Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated
    Billheimer, JT
    Dicker, IB
    Wynn, R
    Bradley, JD
    Cromley, DA
    Godonis, HE
    Grimminger, LC
    He, BK
    Kieras, CJ
    Pedicord, DL
    Spitz, SM
    Thomas, BE
    Zolotarjova, NI
    Gorko, MA
    Hollis, GF
    Daly, RN
    Stern, AM
    Seiffert, D
    [J]. BLOOD, 2002, 99 (10) : 3540 - 3546